TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07246980: Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study

Sponsor: Tulavi Therapeutics,Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1000 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07246980 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07246980 Rescue Dossier →